ClinicalTrials.gg
CompletedNCT02981472Updated Oct 3, 2022Results posted

A Study of the Safety and Pharmacokinetics of Apixaban Versus Vitamin K Antagonist (VKA) or Low Molecular Weight Heparin (LMWH) in Pediatric Subjects With Congenital or Acquired Heart Disease Requiring Anticoagulation

A Phase 2 interventional study of Apixaban and Vitamin K Antagonist (VKA) in Thrombosis, sponsored by Bristol-Myers Squibb. Completed at 46 sites in 14 countries. Open to participants aged 28 Days to 17 Years. Per ClinicalTrials.gov, last updated 2022-10-03.

Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
192
Allocation
Randomized
Ages
28 Days to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing apixaban in Thrombosis — 5 open to participants now, 5 under way, 2 of them phase 3. apixaban · Thrombosis.

Enrollment
8th of 18
192 · median 73
Started
2017
with 1 other
Phase 2
2 of 18
none open now
Registered
8th of 18
by date
Lead sponsor
3 of 18
Bristol-Myers Squibb

Among the 18 studies testing apixaban in Thrombosis, this one is the 8th largest by enrollment, is one of 2 that started in 2017, is one of 2 in phase 2, and was the 8th registered.

Thrombosis

955 studies on the registry are indexed under Thrombosis; 171 are open to participants now.

Browse Thrombosis studies →

Open to participants now

5 of the 18 studies testing apixaban in Thrombosis are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About apixaban

apixaban: first FDA approval 2012 (ELIQUIS), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 126 Thrombosis studies recruiting now, 79 (63%) set no upper age limit and 16 (13%) stop at 75 or younger; 20 take children under 18; 20 take healthy volunteers.

This study: 28 Days to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing apixaban in Thrombosis, or all of them as a file.
02

Study summary

To investigate the safety and pharmacokinetics of apixaban in children with congenital or acquired heart disease who have a need for anticoagulation.

03

Conditions studied

  • Thrombosis

Browse trials for

04

Who can participate

Ages eligible
28 Days to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion criteria

Inclusion Criteria:

  • Males and Females, 28 days to \< 18 years of age, inclusive
  • Congenital or acquired heart diseases requiring chronic anticoagulation for thromboprophylaxis (eg, single ventricle physiology including all 3 stages of palliation, dilated cardiomyopathy, Kawasaki disease with coronary aneurysms, and pulmonary hypertension)
  • Eligible participants include those who newly start anticoagulants and those who are currently on VKA or LMWH or other anticoagulants for thromboprophylaxis
  • Able to tolerate enteral medication [eg, by mouth, nasogastric tube, or gastric tube]
  • Participants 28 days to \< 3 months must be able to tolerate oral/nasogastric tube (NGT)/gastric tube (GT) feeds for at least 5 days prior to randomization

Exclusion criteria

Exclusion Criteria:

  • Recent thromboembolic events less than 6 months prior to enrollment
  • Weight \< 3 kg
  • Use of aggressive life-saving therapies such as ventricular assist devices (VAD) or extracorporeal membrane oxygenation (ECMO) at the time of enrollment
  • Artificial heart valves and mechanical heart valves
  • Known inherited bleeding disorder or coagulopathy (e.g. hemophilia, von Willebrand disease, etc.)
  • Active bleeding at the time of enrollment
  • Any major bleeding other than perioperative in the preceding 3 months
  • Known intracranial congenital vascular malformation or tumor
  • Confirmed diagnosis of a GI ulcer
  • Known antiphospholipid syndrome (APS).

Other protocol defined inclusion/exclusion criteria apply

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
192 participants (actual)

Study arms

  • Experimental
    Apixaban

    Drug: Apixaban

  • Active comparator
    LMWH/VKA

    Drug: Vitamin K Antagonist (VKA) · Drug: Low Molecular Weight Heparin (LMWH)

Interventions

06

What researchers measure

Primary outcomes

  1. Composite of Adjudicated Major or Clinically Relevant Non-Major (CRNM) Bleeding Events

    The number of participants with adjudicated major or CRNM bleeding events per the Perinatal and Paediatric Haemostasis Subcommittee of International Society on Thrombosis and Haemostasis (ISTH) criteria. Events are adjudicated by a blinded, independent events adjudication committee (EAC). Major bleeding satisfies one or more of the following criteria: fatal bleeding, clinically overt bleeding associated with a decrease in hemoglobin of at least 20 g/L (i.e., 2 g/dL) in a 24-hour period, bleeding that is retroperitoneal, pulmonary, intracranial, or otherwise involves the CNS, or bleeding that requires surgical intervention in an operating suite, including interventional radiology. CRNM bleeding satisfies one or both of the following criteria: overt bleeding for which blood product is administered and not directly attributable to the subject's underlying medical condition or bleeding that requires medical or surgical intervention to restore hemostasis, other than in an operating room.

    Time frame: From first dose to 2 days after last dose (Up to approximately 12 months)

Secondary outcomes

  1. The Number of Participants With Thrombotic Events and Thromboembolic Event-Related Death

    The number of participants with thromboembolic events (intra-cardiac, shunt, inside Fontan pathway, pulmonary embolism (PE), stroke, other arterial or venous thromboembolic events, etc.) and thromboembolic event-related death detected by imaging or clinical diagnosis. Death and thromboembolic events are adjudicated by a blinded, independent events adjudication committee (EAC)

    Time frame: From randomization to 2 days after last dose (Up to approximately 12 months)

  2. The Number of Participants With Adjudicated Major Bleeding

    The number of participants with adjudicated major bleeding events per the Perinatal and Paediatric Haemostasis Subcommittee of International Society on Thrombosis and Haemostasis (ISTH) criteria. Major bleeding events are adjudicated by a blinded, independent events adjudication committee (EAC). Major bleeding is defined as bleeding that satisfies one or more of the following criteria: * fatal bleeding * clinically overt bleeding associated with a decrease in hemoglobin of at least 20 g/L (i.e., 2 g/dL) in a 24-hour period * bleeding that is retroperitoneal, pulmonary, intracranial, or otherwise involves the CNS * bleeding that requires surgical intervention in an operating suite, including interventional radiology

    Time frame: From first dose to 2 days after last dose (Up to approximately 12 months)

  3. The Number of Participants With Adjudicated CRNM Bleeding

    The number of participants with adjudicated clinically relevant non-major (CRNM) bleeding events per the Perinatal and Paediatric Haemostasis Subcommittee of International Society on Thrombosis and Haemostasis (ISTH) criteria. CRNM bleeding events are adjudicated by a blinded, independent events adjudication committee (EAC). CRNM bleeding is defined as bleeding that satisfies one or both of the following criteria: * overt bleeding for which blood product is administered and not directly attributable to the subject's underlying medical condition * bleeding that requires medical or surgical intervention to restore hemostasis, other than in an operating room

    Time frame: From first dose to 2 days after last dose (Up to approximately 12 months)

  4. The Number of Participants With All Adjudicated Bleeding

    The number of participants with all adjudicated bleeding events

    Time frame: From first dose to 2 days after last dose (Up to approximately 12 months)

  5. The Number of Participants With Drug Discontinuation Due to Adverse Effects, Intolerability, or Bleeding

    The number of participants with drug discontinuation due to adverse effects, intolerability, or bleeding.

    Time frame: From first dose to 2 days after last dose (Up to approximately 12 months)

  6. The Number of Participant Deaths in the Study

    The number of participant deaths in the study.

    Time frame: From first dose to 2 days after last dose (Up to approximately 12 months)

  7. Maximum Observed Concentration (Cmax)

    Time frame: From first dose up to 6 months after first dose

  8. Trough Observed Concentration (Cmin)

    Time frame: From first dose up to 6 months after first dose

  9. Area Under the Concentration-Time Curve in One Dosing Interval (AUC (TAU))

    Time frame: From first dose up to 6 months after first dose

  10. Time of Maximum Observed Concentration (Tmax)

    Time frame: From first dose up to 6 months after first dose

  11. Anti-FXa Activity

    Anti-FXa Activity was measured to assess participant plasma apixaban levels. 125 participants received at least one dose of apixaban and had anti-FXa samples collected that contributed measurements to at least one of the timepoints below.

    Time frame: From first dose up to 6 months after first dose

  12. Chromogenic FX Assay (Apparent FX Level)

    Chromogenic FX was measured to assess (apparent) FX levels in participants and inhibition of FXa by apixaban. 125 participants received at least one dose of apixaban and had chromogenic FX assay samples collected that contributed measurements to at least one of the timepoints below.

    Time frame: From first dose up to 6 months after first dose

  13. The Child and Parent Reports of Pediatric Quality of Life Inventory (PedsQL)

    Subjects' quality of life was measured using the PedsQL instrument administered only to English-speaking children/parents. Only subjects who completed the questionnaires at both baseline and post-baseline visits were included in the analyses. PedsQL consists of 23 items scored on a 5-point Likert scale from 0 (never) to 4 (almost always) or for the child report for younger children ages 5-7, a 3-point Likert scale: 0 (Not at all), 2 (Sometimes), and 4 (A lot). Scores are reverse scored and transformed to a 0-100 scale as follows: 0=100, 1=75, 3=25, 4=0. Higher scores indicate a better HRQOL and/or lower problems.

    Time frame: from randomization up to 12 months after randomization

  14. Kids Informed Decrease Complications Learning on Thrombosis (KIDCLOT) IMPACT Score

    Subjects' quality of life was measured using the KIDCLOT instrument administered only to English-speaking children/parents. Only subjects who completed the questionnaires at both baseline and post-baseline visits were included in the analyses. KIDCLOT Parent inventory uses a 5 point Likert scale from 1 (N/A), 2 (Never), 3 (Rarely), 4 ( Now and then), 5 (Often). Child inventory uses a 4 point Likert scale 1 (N/A), 2 (Never), 3 (Now and then), 5 (Always). Values are scores as follows 1=0, 2=1, 3=2, 4=3, 5=4. Score interpretation is 0 to 100 percent IMPACT of anticoagulation on a child's life therefore, higher scores indicates a more negative effect.

    Time frame: from randomization up to 12 months after randomization

07

Results

Posted May 18, 2022

Participant flow

Pre-Treatment Period
Participant flow — Pre-Treatment Period
MilestoneApixabanLow Molecular Weight Heparin (LMWH)/Vitamin K Antagonists (VKA)
Started12963
Completed12662
Not completed31
Withdrew: Participant withdrew consent21
Withdrew: Participant no longer meets study criteria10
Treatment Period
Participant flow — Treatment Period
MilestoneApixabanLow Molecular Weight Heparin (LMWH)/Vitamin K Antagonists (VKA)
Started12662
Completed11960
Not completed72
Withdrew: Adverse event61
Withdrew: Participant withdrew consent10
Withdrew: Lost to follow-up01

Outcome measures

PrimaryComposite of Adjudicated Major or Clinically Relevant Non-Major (CRNM) Bleeding Events

The number of participants with adjudicated major or CRNM bleeding events per the Perinatal and Paediatric Haemostasis Subcommittee of International Society on Thrombosis and Haemostasis (ISTH) criteria. Events are adjudicated by a blinded, independent events adjudication committee (EAC). Major bleeding satisfies one or more of the following criteria: fatal bleeding, clinically overt bleeding associated with a decrease in hemoglobin of at least 20 g/L (i.e., 2 g/dL) in a 24-hour period, bleeding that is retroperitoneal, pulmonary, intracranial, or otherwise involves the CNS, or bleeding that requires surgical intervention in an operating suite, including interventional radiology. CRNM bleeding satisfies one or both of the following criteria: overt bleeding for which blood product is administered and not directly attributable to the subject's underlying medical condition or bleeding that requires medical or surgical intervention to restore hemostasis, other than in an operating room.

Time frame:
From first dose to 2 days after last dose (Up to approximately 12 months)
Reported as:
Count of participants · Participants
Composite of Adjudicated Major or Clinically Relevant Non-Major (CRNM) Bleeding Events
ParticipantsApixabanLow Molecular Weight Heparin (LMWH)/Vitamin K Antagonists (VKA)
Composite of Adjudicated Major or Clinically Relevant Non-Major (CRNM) Bleeding Events13
SecondaryThe Number of Participants With Thrombotic Events and Thromboembolic Event-Related Death

The number of participants with thromboembolic events (intra-cardiac, shunt, inside Fontan pathway, pulmonary embolism (PE), stroke, other arterial or venous thromboembolic events, etc.) and thromboembolic event-related death detected by imaging or clinical diagnosis. Death and thromboembolic events are adjudicated by a blinded, independent events adjudication committee (EAC)

Time frame:
From randomization to 2 days after last dose (Up to approximately 12 months)
Reported as:
Count of participants · Participants
The Number of Participants With Thrombotic Events and Thromboembolic Event-Related Death
ParticipantsApixabanLow Molecular Weight Heparin (LMWH)/Vitamin K Antagonists (VKA)
Thromboembolic event00
Thromboembolic event-related death00
SecondaryThe Number of Participants With Adjudicated Major Bleeding

The number of participants with adjudicated major bleeding events per the Perinatal and Paediatric Haemostasis Subcommittee of International Society on Thrombosis and Haemostasis (ISTH) criteria. Major bleeding events are adjudicated by a blinded, independent events adjudication committee (EAC). Major bleeding is defined as bleeding that satisfies one or more of the following criteria: * fatal bleeding * clinically overt bleeding associated with a decrease in hemoglobin of at least 20 g/L (i.e., 2 g/dL) in a 24-hour period * bleeding that is retroperitoneal, pulmonary, intracranial, or otherwise involves the CNS * bleeding that requires surgical intervention in an operating suite, including interventional radiology

Time frame:
From first dose to 2 days after last dose (Up to approximately 12 months)
Reported as:
Count of participants · Participants
The Number of Participants With Adjudicated Major Bleeding
ParticipantsApixabanLow Molecular Weight Heparin (LMWH)/Vitamin K Antagonists (VKA)
The Number of Participants With Adjudicated Major Bleeding11
SecondaryThe Number of Participants With Adjudicated CRNM Bleeding

The number of participants with adjudicated clinically relevant non-major (CRNM) bleeding events per the Perinatal and Paediatric Haemostasis Subcommittee of International Society on Thrombosis and Haemostasis (ISTH) criteria. CRNM bleeding events are adjudicated by a blinded, independent events adjudication committee (EAC). CRNM bleeding is defined as bleeding that satisfies one or both of the following criteria: * overt bleeding for which blood product is administered and not directly attributable to the subject's underlying medical condition * bleeding that requires medical or surgical intervention to restore hemostasis, other than in an operating room

Time frame:
From first dose to 2 days after last dose (Up to approximately 12 months)
Reported as:
Count of participants · Participants
The Number of Participants With Adjudicated CRNM Bleeding
ParticipantsApixabanLow Molecular Weight Heparin (LMWH)/Vitamin K Antagonists (VKA)
The Number of Participants With Adjudicated CRNM Bleeding12
SecondaryThe Number of Participants With All Adjudicated Bleeding

The number of participants with all adjudicated bleeding events

Time frame:
From first dose to 2 days after last dose (Up to approximately 12 months)
Reported as:
Count of participants · Participants
The Number of Participants With All Adjudicated Bleeding
ParticipantsApixabanLow Molecular Weight Heparin (LMWH)/Vitamin K Antagonists (VKA)
The Number of Participants With All Adjudicated Bleeding4723
SecondaryThe Number of Participants With Drug Discontinuation Due to Adverse Effects, Intolerability, or Bleeding

The number of participants with drug discontinuation due to adverse effects, intolerability, or bleeding.

Time frame:
From first dose to 2 days after last dose (Up to approximately 12 months)
Reported as:
Count of participants · Participants
The Number of Participants With Drug Discontinuation Due to Adverse Effects, Intolerability, or Bleeding
ParticipantsApixabanLow Molecular Weight Heparin (LMWH)/Vitamin K Antagonists (VKA)
The Number of Participants With Drug Discontinuation Due to Adverse Effects, Intolerability, or Bleeding71
SecondaryThe Number of Participant Deaths in the Study

The number of participant deaths in the study.

Time frame:
From first dose to 2 days after last dose (Up to approximately 12 months)
Reported as:
Count of participants · Participants
The Number of Participant Deaths in the Study
ParticipantsApixabanLow Molecular Weight Heparin (LMWH)/Vitamin K Antagonists (VKA)
The Number of Participant Deaths in the Study00
SecondaryMaximum Observed Concentration (Cmax)
Time frame:
From first dose up to 6 months after first dose
Reported as:
Geometric mean · ng/mL
Maximum Observed Concentration (Cmax)
ng/mLParticipants Weight Range 6 to < 9 kgParticipants Weight Range 9 to < 12 kgParticipants Weight Range 12 to < 18 kgParticipants Weight Range 18 to < 25 kgParticipants Weight Range 25 to < 35 kgParticipants Weight Range ≥ 35 kg
Maximum Observed Concentration (Cmax)185 ± 48.8218 ± 23.4222 ± 39.6244 ± 30.7249 ± 37.7203 ± 35.9
SecondaryTrough Observed Concentration (Cmin)
Time frame:
From first dose up to 6 months after first dose
Reported as:
Geometric mean · ng/mL
Trough Observed Concentration (Cmin)
ng/mLParticipants Weight Range 6 to < 9 kgParticipants Weight Range 9 to < 12 kgParticipants Weight Range 12 to < 18 kgParticipants Weight Range 18 to < 25 kgParticipants Weight Range 25 to < 35 kgParticipants Weight Range ≥ 35 kg
Trough Observed Concentration (Cmin)57.9 ± 90.382.7 ± 21.564.3 ± 69.567.4 ± 58.973.1 ± 64.772.7 ± 46.8
SecondaryArea Under the Concentration-Time Curve in One Dosing Interval (AUC (TAU))
Time frame:
From first dose up to 6 months after first dose
Reported as:
Geometric mean · ng • h/mL
Area Under the Concentration-Time Curve in One Dosing Interval (AUC (TAU))
ng • h/mLParticipants Weight Range 6 to < 9 kgParticipants Weight Range 9 to < 12 kgParticipants Weight Range 12 to < 18 kgParticipants Weight Range 18 to < 25 kgParticipants Weight Range 25 to < 35 kgParticipants Weight Range ≥ 35 kg
Area Under the Concentration-Time Curve in One Dosing Interval (AUC (TAU))1460 ± 61.21840 ± 20.71610 ± 49.61760 ± 38.31840 ± 43.31630 ± 37.3
SecondaryTime of Maximum Observed Concentration (Tmax)
Time frame:
From first dose up to 6 months after first dose
Reported as:
Median · hours
Time of Maximum Observed Concentration (Tmax)
hoursParticipants Weight Range 6 to < 9 kgParticipants Weight Range 9 to < 12 kgParticipants Weight Range 12 to < 18 kgParticipants Weight Range 18 to < 25 kgParticipants Weight Range 25 to < 35 kgParticipants Weight Range ≥ 35 kg
Time of Maximum Observed Concentration (Tmax)2.24 (1.41 to 2.83)2.47 (2.23 to 2.71)1.72 (0.938 to 3.35)1.74 (0.775 to 2.18)1.65 (1.26 to 2.85)1.85 (1.47 to 2.93)
SecondaryAnti-FXa Activity

Anti-FXa Activity was measured to assess participant plasma apixaban levels. 125 participants received at least one dose of apixaban and had anti-FXa samples collected that contributed measurements to at least one of the timepoints below.

Time frame:
From first dose up to 6 months after first dose
Reported as:
Mean · ng/mL
Anti-FXa Activity
ng/mLApixaban
Day 1 (4 HRS POSTDOSE)147.69 ± 7.243
Week 2 (PREDOSE)86.24 ± 7.652
Week 2 (2 HRS POSTDOSE)242.34 ± 18.966
Month 3 (2 HRS POSTDOSE)228.88 ± 14.263
Month 6 (PREDOSE)66.93 ± 6.532
SecondaryChromogenic FX Assay (Apparent FX Level)

Chromogenic FX was measured to assess (apparent) FX levels in participants and inhibition of FXa by apixaban. 125 participants received at least one dose of apixaban and had chromogenic FX assay samples collected that contributed measurements to at least one of the timepoints below.

Time frame:
From first dose up to 6 months after first dose
Reported as:
Mean · Percent
Chromogenic FX Assay (Apparent FX Level)
PercentApixaban
Day 1 (PREDOSE)58.87 ± 2.368
Day 1 (4 HRS POSTDOSE)18.90 ± 1.205
Week 2 (PREDOSE)35.88 ± 1.973
Week 2 (2 HRS POSTDOSE)21.26 ± 1.680
Month 3 (2 HRS POSTDOSE)18.25 ± 0.970
Month 6 (PREDOSE)36.57 ± 1.943
SecondaryThe Child and Parent Reports of Pediatric Quality of Life Inventory (PedsQL)

Subjects' quality of life was measured using the PedsQL instrument administered only to English-speaking children/parents. Only subjects who completed the questionnaires at both baseline and post-baseline visits were included in the analyses. PedsQL consists of 23 items scored on a 5-point Likert scale from 0 (never) to 4 (almost always) or for the child report for younger children ages 5-7, a 3-point Likert scale: 0 (Not at all), 2 (Sometimes), and 4 (A lot). Scores are reverse scored and transformed to a 0-100 scale as follows: 0=100, 1=75, 3=25, 4=0. Higher scores indicate a better HRQOL and/or lower problems.

Time frame:
from randomization up to 12 months after randomization
Reported as:
Mean · Score on a scale
The Child and Parent Reports of Pediatric Quality of Life Inventory (PedsQL)
Score on a scaleApixabanLow Molecular Weight Heparin (LMWH)/Vitamin K Antagonists (VKA)
GENERAL-SPECIFIC MODULE ASSESSED BY CHILD - BASELINE69.64 ± 15.51260.71 ± 17.374
GENERAL-SPECIFIC MODULE ASSESSED BY CHILD - MONTH 1273.37 ± 19.99864.81 ± 22.327
GENERAL-SPECIFIC MODULE ASSESSED BY PARENT - BASELINE65.61 ± 16.62565.42 ± 18.000
GENERAL-SPECIFIC MODULE ASSESSED BY PARENT - MONTH 1270.00 ± 19.56070.32 ± 21.949
HEART PROBLEMS AND TREATMENT ASSESSED BY CHILD - BASELINE65.34 ± 22.13064.70 ± 18.465
HEART PROBLEMS AND TREATMENT ASSESSED BY CHILD - MONTH 1269.46 ± 21.11963.44 ± 19.836
TREATMENT II ASSESSED BY CHILD - BASELINE87.39 ± 22.99485.68 ± 15.857
TREATMENT II ASSESSED BY CHILD - MONTH 1291.77 ± 10.89686.27 ± 16.400
PERCEIVED PHYSICAL APPEARANCE ASSESSED BY CHILD - BASELINE75.51 ± 27.47778.44 ± 23.390
PERCEIVED PHYSICAL APPEARANCE ASSESSED BY CHILD - MONTH 1280.56 ± 22.40881.37 ± 30.689
TREATMENT ANXIETY ASSESSED BY CHILD - BASELINE80.52 ± 23.42060.31 ± 34.162
TREATMENT ANXIETY ASSESSED BY CHILD - MONTH 1280.71 ± 25.48060.31 ± 38.333
COGNITIVE PROBLEMS ASSESSED BY CHILD - BASELINE69.85 ± 20.87153.24 ± 20.382
COGNITIVE PROBLEMS ASSESSED BY CHILD - MONTH 1268.24 ± 24.36753.53 ± 26.796
COMMUNICATION ASSESSED BY CHILD - BASELINE66.15 ± 30.00063.55 ± 28.998
COMMUNICATION ASSESSED BY CHILD - MONTH 1270.31 ± 26.68157.28 ± 38.948
HEART PROBLEMS AND TREATMENT ASSESSED BY PARENT - BASELINE63.68 ± 20.72767.71 ± 22.668
HEART PROBLEMS AND TREATMENT ASSESSED BY PARENT - MONTH 1266.37 ± 20.81169.00 ± 23.688
TREATMENT II ASSESSED BY PARENT - BASELINE91.41 ± 11.55785.27 ± 17.325
TREATMENT II ASSESSED BY PARENT - MONTH 1290.30 ± 12.38183.80 ± 18.915
PERCEIVED PHYSICAL APPEARANCE ASSESSED BY PARENT - BASELINE79.16 ± 22.57179.66 ± 22.958
PERCEIVED PHYSICAL APPEARANCE ASSESSED BY PARENT - MONTH 1279.38 ± 21.01274.33 ± 26.998
TREATMENT ANXIETY ASSESSED BY PARENT - BASELINE61.44 ± 30.80456.27 ± 33.997
TREATMENT ANXIETY ASSESSED BY PARENT - MONTH 1264.03 ± 29.56757.77 ± 34.199
COGNITIVE PROBLEMS ASSESSED BY PARENT - BASELINE60.29 ± 29.55861.60 ± 25.807
COGNITIVE PROBLEMS ASSESSED BY PARENT - MONTH 1258.69 ± 29.56058.53 ± 33.432
COMMUNICATION ASSESSED BY PARENT - BASELINE65.57 ± 27.34267.33 ± 28.257
COMMUNICATION ASSESSED BY PARENT - MONTH 1268.20 ± 24.03766.17 ± 28.067
SecondaryKids Informed Decrease Complications Learning on Thrombosis (KIDCLOT) IMPACT Score

Subjects' quality of life was measured using the KIDCLOT instrument administered only to English-speaking children/parents. Only subjects who completed the questionnaires at both baseline and post-baseline visits were included in the analyses. KIDCLOT Parent inventory uses a 5 point Likert scale from 1 (N/A), 2 (Never), 3 (Rarely), 4 ( Now and then), 5 (Often). Child inventory uses a 4 point Likert scale 1 (N/A), 2 (Never), 3 (Now and then), 5 (Always). Values are scores as follows 1=0, 2=1, 3=2, 4=3, 5=4. Score interpretation is 0 to 100 percent IMPACT of anticoagulation on a child's life therefore, higher scores indicates a more negative effect.

Time frame:
from randomization up to 12 months after randomization
Reported as:
Mean · Score on a scale
Kids Informed Decrease Complications Learning on Thrombosis (KIDCLOT) IMPACT Score
Score on a scaleApixabanLow Molecular Weight Heparin (LMWH)/Vitamin K Antagonists (VKA)
BASELINE CHILD REPORTED - 6 MONTHS24.35 ± 12.88726.45 ± 12.114
POST BASELINE CHILD REPORTED - 6 MONTHS22.81 ± 13.38022.57 ± 16.049
BASELINE CHILD REPORTED - 12 MONTHS22.50 ± 11.78725.32 ± 11.719
POST BASELINE CHILD REPORTED - 12 MONTHS21.52 ± 13.25118.01 ± 10.408
BASELINE PARENT REPORTED - 6 MONTHS37.97 ± 20.49339.02 ± 17.932
POST BASELINE PARENT REPORTED - 6 MONTHS32.32 ± 17.06037.94 ± 20.626
BASELINE PARENT REPORTED - 12 MONTHS38.37 ± 18.87439.36 ± 16.057
POST BASELINE PARENT REPORTED - 12 MONTHS31.10 ± 16.02133.61 ± 17.943

Adverse events

Collected over AEs are collected from the first dose date until the last dose date + 2 days/ SAEs are collected from the first dose date until the last dose date + 30 days (Up to approximately 13 months) Participants were assessed for All Cause Mortality from their first dose until the study was completed (up to approximately 57 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Apixaban0/126 (0%)26/126 (20.6%)68/126 (54%)
Low Molecular Weight Heparin (LMWH)/Vitamin K Antagonists (VKA)0/62 (0%)13/62 (21%)36/62 (58.1%)
Most frequent serious events
Showing 10 of 54
Most frequent serious events
EventApixabanLow Molecular Weight Heparin (LMWH)/Vitamin K Antagonists (VKA)
ArrhythmiaCardiac disorders1/1261/62
Atrial septal defect acquiredCardiac disorders0/1261/62
Supraventricular tachycardiaCardiac disorders0/1261/62
Congenital cystic kidney diseaseCongenital, familial and genetic disorders0/1261/62
Hypoplastic left heart syndromeCongenital, familial and genetic disorders0/1261/62
Gingival bleedingGastrointestinal disorders0/1261/62
HaematocheziaGastrointestinal disorders0/1261/62
Protein-losing gastroenteropathyGastrointestinal disorders1/1261/62
COVID-19Infections and infestations1/1261/62
InfluenzaInfections and infestations1/1261/62
Most frequent other events
Showing 10 of 13
Most frequent other events
EventApixabanLow Molecular Weight Heparin (LMWH)/Vitamin K Antagonists (VKA)
VomitingGastrointestinal disorders20/1269/62
PyrexiaGeneral disorders20/1268/62
EpistaxisRespiratory, thoracic and mediastinal disorders20/1266/62
HeadacheNervous system disorders19/1263/62
NasopharyngitisInfections and infestations13/1268/62
Upper respiratory tract infectionInfections and infestations14/1264/62
DiarrhoeaGastrointestinal disorders12/1264/62
ContusionInjury, poisoning and procedural complications9/1265/62
GastroenteritisInfections and infestations7/1264/62
International normalised ratio increasedInvestigations0/1264/62

Baseline characteristics

Age, Continuous
Age, Continuous(Years)ApixabanLow Molecular Weight Heparin (LMWH)/Vitamin K Antagonists (VKA)Total
Mean7.96 ± 4.5537.56 ± 4.4087.83 ± 4.499
Age, Customized
Age, Customized(Participants)ApixabanLow Molecular Weight Heparin (LMWH)/Vitamin K Antagonists (VKA)Total
28 DAYS - < 2 YEARS8311
2 YEARS - < 6 YEARS402262
6 YEARS - < 12 YEARS492372
12 YEARS - < 18 YEARS321547
Sex: Female, Male
Sex: Female, Male(Participants)ApixabanLow Molecular Weight Heparin (LMWH)/Vitamin K Antagonists (VKA)Total
Female672390
Male6240102
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)ApixabanLow Molecular Weight Heparin (LMWH)/Vitamin K Antagonists (VKA)Total
Hispanic or Latino201434
Not Hispanic or Latino10547152
Unknown or Not Reported426
Race (NIH/OMB)
Race (NIH/OMB)(Participants)ApixabanLow Molecular Weight Heparin (LMWH)/Vitamin K Antagonists (VKA)Total
American Indian or Alaska Native101
Asian6410
Native Hawaiian or Other Pacific Islander000
Black or African American729
White10951160
More than one race000
Unknown or Not Reported6612
08

Study locations

46 sites
  • Phoenix Children'S Hospital
    Phoenix, Arizona 85016, United States
  • University Of California San Diego
    La Jolla, California 92093-0641, United States
  • Children'S Hospital Colorado
    Aurora, Colorado 80045, United States
  • Childrens Healthcare Of Atlanta
    Atlanta, Georgia 30322, United States
  • Local Institution - 0008
    Indianapolis, Indiana 46202, United States
  • Local Institution - 0009
    Boston, Massachusetts 02115, United States
  • Local Institution - 0013
    Ann Arbor, Michigan 48109, United States
  • Childrens Mercy Hospital
    Kansas City, Missouri 64108, United States
  • Local Institution - 0006
    Cincinnati, Ohio 45229, United States
  • Childrens Hospital Of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
  • Local Institution - 0012
    Charleston, South Carolina 29425, United States
  • Local Institution - 0011
    Houston, Texas 77030-2399, United States
  • Primary Children's Hospital
    Salt Lake City, Utah 84113, United States
  • Local Institution - 0055
    Seattle, Washington 98105, United States
  • Local Institution
    Caba, Buenos Aires 1426, Argentina
  • Local Institution - 0030
    Parkville, Victoria 3052, Australia
  • Local Institution - 0001
    Vienna, 1090, Austria
  • Local Institution - 0022
    Curitiba, Parana 80250-060, Brazil
  • Instituto De Cardiologia Do Rio Grande Do Sul
    Porto Alegre, Rio Grande Do Sul 90620-001, Brazil
  • Local Institution - 0020
    Campinas, Sao Paulo 13060-080, Brazil
  • Instituto de Pesquisa PENSI
    Sao Paulo, 01227-200, Brazil
  • Universidade Federal De Sao Paulo
    Sao Paulo, 04024-002, Brazil
  • Local Institution - 0015
    Toronto, Ontario M5G 1X8, Canada
  • Local Institution - 0031
    HUS, 00029, Finland
  • Local Institution - 0002
    Freiburg, 79106, Germany
  • Local Institution - 0004
    Hamburg, 20246, Germany
  • Local Institution - 0003
    Muenchen, 80636, Germany
  • Local Institution - 0047
    Petach Tikva, 0, Israel
  • Local Institution - 0046
    Tel Hashomer, 52620, Israel
  • Local Institution - 0026
    Rome, Roma 00165, Italy
  • Local Institution - 0028
    Bologna, 40138, Italy
  • Local Institution - 0027
    Milano, 20097, Italy
  • Local Institution - 0018
    Mexico City, Distrito Federal 04530, Mexico
  • Local Institution - 0019
    Mexico City, Distrito Federal 06720, Mexico
  • Local Institution - 0016
    Mexico City, Distrito Federal 14080, Mexico
  • Local Institution - 0044
    Leon, Guanajuato 37000, Mexico
  • Local Institution - 0062
    Ekaterinburg, 620134, Russian Federation
  • Local Institution
    Kazan, 420012, Russian Federation
  • Local Institution
    Kemerovo, 650002, Russian Federation
  • Local Institution - 0057
    Novosibirsk, 630055, Russian Federation
  • Local Institution - 0049
    Barcelona, 08950, Spain
  • Local Institution
    Madrid, 28007, Spain
  • Local Institution - 0048
    Madrid, 28046, Spain
  • Local Institution - 0040
    Leicester, Leicestershire LE3 9QP, United Kingdom
  • Local Institution - 0042
    Bristol, Somerset BS2 8BJ, United Kingdom
  • Local Institution
    Manchester, M13 9WL, United Kingdom
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2017 to primary completion in Oct 2021, 56 months.

Results were first posted in May 2022, 7 months after primary completion.

Of 22 phase 2 interventional studies under Thrombosis, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 56. This study's 56 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2016
First posted
Dec 5, 2016
StartActual
Jan 19, 2017
Primary completionActual
Oct 18, 2021
CompletionActual
Oct 18, 2021
Results first posted
May 18, 2022
Last update
Oct 3, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 3, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02981472
Collaborators
Pediatric Heart Network, Pfizer
Responsible party
Sponsor
First posted
Dec 5, 2016
Start date
Jan 19, 2017
Primary completion
Oct 18, 2021
Completion
Oct 18, 2021
Results posted
May 18, 2022
Last update
Oct 3, 2022

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apixaban

Start the discussion